Upgrade to Finviz Elite: Get our fastest platform speed, real-time data, and unlimited screening & charting. Start Free Trial

Open in Screener

BDTX

Black Diamond Therapeutics Inc

Feb 13 • 04:00PM ET

2.22

+0.03 1.37 %

Healthcare • Biotechnology • USA • NASD

Peers: BPMC FATE IGMS ALLO ADAP TVRD XFOR CRBP

| Held by: VTI VXF FESM IBB BSVO DFAS PRFZ IWC DFSV EES

Index	-	P/E	6.12	EPS (ttm)	0.36	Insider Own	21.46%	Shs Outstand	56.94M	Perf Week	-1.55%
Market Cap	126.48M	Forward P/E	-	EPS next Y	-0.63	Insider Trans	0.00%	Shs Float	44.75M	Perf Month	-20.43%
Enterprise Value	10.65M	PEG	-	EPS next Q	-0.18	Inst Own	65.10%	Short Float	9.24%	Perf Quarter	-54.41%
Income	21.50M	P/S	1.81	EPS this Y	135.14%	Inst Trans	-0.63%	Short Ratio	3.52	Perf Half Y	-20.43%
Sales	70.00M	P/B	1.00	EPS next Y	-241.20%	ROA	14.54%	Short Interest	4.13M	Perf YTD	-8.64%
Book/sh	2.22	P/C	0.93	EPS next 5Y	11.38%	ROE	19.23%	52W High	4.94 -55.06%	Perf Year	-5.13%
Cash/sh	2.38	P/FCF	5.92	EPS past 3/5Y	28.55% -5.22%	ROIC	15.12%	52W Low	1.20 85.77%	Perf 3Y	-23.97%
Dividend Est.	-	EV/EBITDA	0.87	Sales past 3/5Y	- -	Gross Margin	99.51%	Volatility	4.94% 5.99%	Perf 5Y	-91.72%
Dividend TTM	-	EV/Sales	0.15	EPS Y/Y TTM	127.88%	Oper. Margin	16.94%	ATR (14)	0.15	Perf 10Y	-
Dividend Ex-Date	-	Quick Ratio	8.94	Sales Y/Y TTM	-	Profit Margin	30.71%	RSI (14)	37.20	Recom	1.33
Dividend Gr. 3/5Y	- -	Current Ratio	8.94	EPS Q/Q	45.77%	SMA20	-8.73%	Beta	3.37	Target Price	9.29
Payout	-	Debt/Eq	0.16	Sales Q/Q	-	SMA50	-13.26%	Rel Volume	0.41	Prev Close	2.19
Employees	24	LT Debt/Eq	0.13	Earnings	Nov 06 BMO	SMA200	-23.36%	Avg Volume	1.17M	Price	2.22
IPO	Jan 30, 2020	Option/Short	Yes / Yes	EPS/Sales Surpr.	35.98% -	Trades		Volume	476,650	Change	1.37%

Date	Action	Analyst	Rating Change	Price Target Change
Dec-03-25	Downgrade	Guggenheim	Buy → Neutral
Nov-18-25	Resumed	Piper Sandler	Overweight	$9
Oct-16-25	Resumed	Stifel	Buy	$8
Sep-04-25	Initiated	Guggenheim	Buy	$8
Jul-01-25	Resumed	Raymond James	Outperform	$11
Jul-31-24	Initiated	Raymond James	Outperform	$20
Jul-14-23	Initiated	Piper Sandler	Overweight
Jun-30-23	Upgrade	Stifel	Hold → Buy	$2 → $10
Jun-28-23	Upgrade	H.C. Wainwright	Neutral → Buy	$11
Jun-27-23	Upgrade	Wedbush	Neutral → Outperform	$10
Mar-29-22	Downgrade	Wedbush	Outperform → Neutral
Mar-22-22	Downgrade	H.C. Wainwright	Buy → Neutral
Sep-30-21	Initiated	Stifel	Hold	$10
Jan-07-21	Initiated	Wedbush	Outperform	$45
Nov-24-20	Initiated	Berenberg	Buy	$58
May-04-20	Initiated	H.C. Wainwright	Buy	$53
Feb-24-20	Initiated	JP Morgan	Overweight	$42
Feb-24-20	Initiated	Jefferies	Buy
Feb-24-20	Initiated	Cowen	Outperform
Feb-24-20	Initiated	Canaccord Genuity	Buy	$50

Show Previous Ratings

Feb-02-26 09:56AM	Black Diamond Therapeutics, Inc. (BDTX) Price Target Trimmed as Piper Updates Biotech Models and 2026 Catalyst Tracker (Insider Monkey)
Jan-23-26 09:40AM	Is Black Diamond Therapeutics (BDTX) Stock Outpacing Its Medical Peers This Year? (Zacks)
Jan-09-26 12:00PM	What Makes Black Diamond (BDTX) a New Strong Buy Stock (Zacks)
06:23AM	New Strong Buy Stocks for January 9th (Zacks)
Dec-31-25 11:12AM	Black Diamond Therapeutics' Silevertinib Shows 60% Response Rate in Preliminary Phase 2 Lung Cancer Data (Insider Monkey)
09:35AM	Loading…
Dec-04-25 09:35AM	Down 30.5% in 4 Weeks, Here's Why You Should You Buy the Dip in Black Diamond (BDTX) (Zacks)
Dec-03-25 07:01AM	Black Diamond Therapeutics Announces Preliminary Phase 2 Data for Silevertinib in 1L NSCLC and Plans for a Phase 2 Trial of Silevertinib in GBM (GlobeNewswire) -22.03%
Dec-02-25 04:01PM	Black Diamond Therapeutics to Host Webcast Presentation Highlighting Silevertinib Phase 2 Clinical Trial Results and Program Update (GlobeNewswire) -8.49%
Nov-28-25 09:40AM	Is ANI Pharmaceuticals (ANIP) Stock Outpacing Its Medical Peers This Year? (Zacks)
Nov-12-25 09:40AM	Is ANI Pharmaceuticals (ANIP) Outperforming Other Medical Stocks This Year? (Zacks) +5.41%
09:15AM	Black Diamond Therapeutics, Inc. (BDTX) Hits Fresh High: Is There Still Room to Run? (Zacks)
Nov-06-25 04:01PM	Black Diamond Therapeutics to Participate in Upcoming Investor Conferences (GlobeNewswire)
07:37AM	Black Diamond: Q3 Earnings Snapshot (Associated Press Finance)
07:30AM	Black Diamond Therapeutics Reports Third Quarter 2025 Financial Results and Provides Corporate Update (GlobeNewswire)
Oct-31-25 02:00PM	Should You Buy, Hold, or Sell BDTX Stock Ahead of Q3 Earnings? (Zacks)
09:24AM	Loading…
Oct-22-25 09:24AM	BDTX vs. ORIC: Which Oncology Focused Biotech Stock Is a Better Pick Now? (Zacks) -5.05%
Oct-15-25 09:20AM	Can NSCLC Drug Silevertinib Drive Sustainable Growth for BDTX? (Zacks) +10.37%
Oct-09-25 09:52AM	BDTX Stock Hits 52 Week High: Is There More Room for Growth? (Zacks) +8.27%
09:40AM	Is Medpace (MEDP) Outperforming Other Medical Stocks This Year? (Zacks)
Oct-07-25 09:15AM	Black Diamond Therapeutics, Inc. (BDTX) Hit a 52 Week High, Can the Run Continue? (Zacks)
Sep-25-25 12:53PM	Will BDTX's EGFR Inhibitor Bring a Paradigm Shift in NSCLC Treatment? (Zacks)
Sep-23-25 10:23AM	BDTX vs. Cullinan Therapeutic: Which EGFR Challenger Is the Better Buy? (Zacks) -7.31%
Sep-22-25 09:40AM	Has Black Diamond Therapeutics (BDTX) Outpaced Other Medical Stocks This Year? (Zacks)
Sep-16-25 09:47AM	Guggenheim Sets $8 Price Target as Black Diamond Therapeutics, Inc. (BDTX) Prepares Phase 2 Results (Insider Monkey)
Sep-12-25 09:08AM	Is BDTX's Cash balance Enough to Successfully Develop Its NSCLC Drug? (Zacks)
Sep-05-25 10:53AM	BDTX Stock Surges 51.1% in Six Months: Is There More Room for Growth? (Zacks)
Sep-04-25 10:46AM	Is the Recent Pipeline Progress on its NSCLC Drug Enough for BDTX? (Zacks)
Aug-19-25 12:00PM	Black Diamond (BDTX) Upgraded to Strong Buy: Here's Why (Zacks)
Aug-18-25 09:40AM	Are Medical Stocks Lagging Black Diamond Therapeutics (BDTX) This Year? (Zacks)
Aug-07-25 07:47AM	Black Diamond: Q2 Earnings Snapshot (Associated Press Finance) -15.24%
07:30AM	Loading…
07:30AM	Black Diamond Therapeutics Reports Second Quarter 2025 Financial Results and Provides Corporate Update (GlobeNewswire)
Jul-15-25 04:58PM	Black Diamond Therapeutics, Inc. (BDTX) Rated Outperform as Lead Drug Shows Promise (Insider Monkey)
May-29-25 08:00AM	Black Diamond Therapeutics to Participate in Jefferies Global Healthcare Conference (GlobeNewswire) +13.07%
May-12-25 04:05PM	Black Diamond Therapeutics Reports First Quarter 2025 Financial Results and Provides Corporate Update (GlobeNewswire) +6.71% +10.29%
Apr-26-25 11:00AM	Microsoft, Apple Set To Report Earnings As Markets Watch Out For Core PCE Price Index (Seeking Alpha)
Mar-31-25 08:00AM	Black Diamond Therapeutics to Participate in Upcoming Investor Conferences (GlobeNewswire)
Mar-25-25 12:58AM	Black Diamond Therapeutics Trades Well Below Cash After Lucrative Deal With Servier (SeekingAlpha)
Mar-20-25 10:42AM	Servier and Black Diamond sign deal for solid tumours therapy (Pharmaceutical Technology) +9.30%
Mar-19-25 07:00AM	Servier and Black Diamond Therapeutics Announce Global Licensing Agreement for BDTX-4933, A Targeted Oncology Therapy (GlobeNewswire)
Mar-06-25 04:09PM	Black Diamond: Q4 Earnings Snapshot (Associated Press Finance)
04:01PM	Black Diamond Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Corporate Update (GlobeNewswire)
Feb-19-25 09:15AM	NAYA Biosciences Announces Nomination of New Board Members (GlobeNewswire)
Jan-12-25 06:05AM	Raymond James Predicts Up to ~930% Rally for These 2 Strong Buy Stocks (TipRanks)
Nov-05-24 09:00AM	Black Diamond: Q3 Earnings Snapshot (Associated Press Finance) +8.70%
08:00AM	Black Diamond Therapeutics Reports Third Quarter 2024 Financial Results and Provides Corporate Update (GlobeNewswire)
Nov-01-24 08:00AM	Black Diamond Therapeutics to Participate in Upcoming Investor Conferences (GlobeNewswire) +5.47%
Oct-07-24 04:01PM	Black Diamond Therapeutics Announces Restructuring Plan to Focus Resources on BDTX-1535 and Extend Cash Runway (GlobeNewswire)
Sep-23-24 11:43AM	Black Diamond Therapeutics' Lead Drug Candidate Shows Initial Anti-tumor Activity In Certain Type Of Lung Cancer Resistant To AstraZeneca's Drug (Benzinga) -5.46%
07:00AM	Black Diamond Therapeutics Announces Initial Phase 2 Data Demonstrating Robust Anti-tumor Activity of BDTX-1535 in Patients with Recurrent EGFRm NSCLC who Present with a Broad Spectrum of Classical, Non-classical, and C797S Resistance Mutations (GlobeNewswire)
Sep-22-24 10:00AM	Black Diamond Therapeutics to Host Webcast Presentation of Initial Phase 2 BDTX-1535 Data in Patients With Recurrent EGFRm NSCLC (GlobeNewswire)
Sep-14-24 03:30AM	Black Diamond Therapeutics Presents Real-World Treatment Practices and Patient Outcomes in Newly Diagnosed NSCLC Patients with Non-Classical Mutations at the European Society for Medical Oncology (ESMO) Congress 2024 (GlobeNewswire)
Aug-08-24 04:05PM	Gyre Therapeutics Announces Appointment of David M. Epstein, Ph.D., to Board of Directors (GlobeNewswire) +6.25%
12:00PM	All You Need to Know About Black Diamond (BDTX) Rating Upgrade to Buy (Zacks)
Aug-06-24 01:53PM	BDTX Stock Earnings: Black Diamond Therapeutic Beats EPS for Q2 2024 (InvestorPlace) -5.57%
07:37AM	Black Diamond: Q2 Earnings Snapshot (Associated Press Finance)
07:30AM	Black Diamond Therapeutics Reports Second Quarter 2024 Financial Results and Provides Corporate Update (GlobeNewswire)
Jun-29-24 08:28PM	Is Black Diamond Therapeutics, Inc. (BDTX) a Good Biotech Penny Stock to Buy Right Now? (Insider Monkey)
06:30PM	10 Best Biotech Penny Stocks to Buy Now (Insider Monkey)
Jun-01-24 10:00AM	Black Diamond Therapeutics Presents Promising BDTX-1535 Clinical Data in Patients with Recurrent Glioblastoma at 2024 American Society of Clinical Oncology (ASCO) Annual Meeting (GlobeNewswire)
May-29-24 08:00AM	Black Diamond Therapeutics to Participate in Jefferies Global Healthcare Conference (GlobeNewswire)
May-16-24 08:23AM	HC Wainwright Adjusts Price Target on Black Diamond Therapeutics to $11 From $12, Keeps Buy Rating (MT Newswires)
May-10-24 08:46AM	Should You Buy Black Diamond Therapeutics (BDTX) Ahead of Earnings? (Zacks) -9.48%
May-09-24 01:54PM	BDTX Stock Earnings: Black Diamond Therapeutic Beats EPS for Q1 2024 (InvestorPlace)
07:30AM	Black Diamond Therapeutics Reports First Quarter 2024 Financial Results and Provides Corporate Update (GlobeNewswire)
07:28AM	Black Diamond: Q1 Earnings Snapshot (Associated Press Finance)
Apr-29-24 08:50AM	Black Diamond (BDTX) is on the Move, Here's Why the Trend Could be Sustainable (Zacks)
Apr-25-24 09:55AM	Does Black Diamond (BDTX) Have the Potential to Rally 152.96% as Wall Street Analysts Expect? (Zacks)
Apr-24-24 04:05PM	Black Diamond Therapeutics Announces Presentations at the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting (GlobeNewswire)
Apr-23-24 07:45AM	Garry Menzel joins GHO Capital as Operating Partner (GlobeNewswire)
Apr-15-24 12:00PM	Black Diamond (BDTX) Upgraded to Buy: What Does It Mean for the Stock? (Zacks)
Apr-11-24 08:00AM	Black Diamond Therapeutics Announces Changes to Board of Directors (GlobeNewswire) +11.85%
Apr-08-24 09:55AM	Wall Street Analysts Predict a 129.25% Upside in Black Diamond (BDTX): Here's What You Should Know (Zacks) +5.73%
Apr-07-24 06:00PM	Black Diamond Therapeutics Presents Novel Real-World Evidence of the Evolving EGFR Mutation Landscape in NSCLC and the Opportunity for BDTX-1535 in an Oral Presentation at the 2024 American Association of Cancer Research Annual Meeting (GlobeNewswire)
Apr-03-24 08:00AM	Black Diamond Therapeutics to Participate in Upcoming Investor Conferences (GlobeNewswire) +5.71%
Mar-22-24 09:55AM	How Much Upside is Left in Black Diamond Therapeutics (BDTX)? Wall Street Analysts Think 95.93% (Zacks) +6.10%
Mar-14-24 05:31AM	Black Diamond Therapeutics Inc (BDTX) Reports Q4 and Full Year 2023 Financials, Advances ... (GuruFocus.com) +8.35%
Mar-12-24 08:32AM	Black Diamond: Q4 Earnings Snapshot (Associated Press Finance) -5.50%
08:00AM	Black Diamond Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Corporate Update (GlobeNewswire)
Mar-05-24 04:30PM	Black Diamond Therapeutics Announces Upcoming Presentation at AACR Annual Meeting 2024 (GlobeNewswire)
Feb-28-24 08:00AM	Black Diamond Therapeutics to Participate in the TD Cowen 44th Annual Health Care Conference (GlobeNewswire)
Jan-04-24 08:00AM	Black Diamond Therapeutics Announces Corporate Update and Expected 2024 Milestones (GlobeNewswire)
Dec-13-23 07:00AM	Black Diamond Therapeutics Announces Topline Results from Phase 1 Dose Escalation Trial of BDTX-1535 in Patients with Recurrent GBM (GlobeNewswire) -9.03%
Nov-07-23 08:00AM	Black Diamond Therapeutics to Participate in Upcoming Investor Conferences (GlobeNewswire)
Nov-06-23 08:07AM	Black Diamond Therapeutics Inc (BDTX) Reports Q3 2023 Financial Results and Corporate Update (GuruFocus.com)
07:48AM	Black Diamond: Q3 Earnings Snapshot (Associated Press Finance)
07:45AM	Black Diamond Therapeutics Reports Third Quarter 2023 Financial Results and Provides Corporate Update (GlobeNewswire)
Oct-20-23 12:54PM	Hedge Fund and Insider Trading News: John Paulson, Sanjay Shah, Doug Kass, Point72 Asset Management, Balyasny Asset Management, Black Diamond Therapeutics, Inc. (BDTX), Delta Air Lines, Inc. (DAL), and More (Insider Monkey)
Oct-14-23 12:30PM	Black Diamond Therapeutics Presents Dose Escalation Data Demonstrating Durable Responses in Patients with NSCLC from Phase 1 Trial of BDTX-1535 (GlobeNewswire)
Oct-04-23 12:14PM	Black Diamond Therapeutics to Present Preclinical and Clinical Data at the AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics (GlobeNewswire) -5.56%
Sep-18-23 12:34PM	Co-founder of cancer biotech Black Diamond replaced as CEO (American City Business Journals)
07:00AM	Black Diamond Therapeutics Announces CEO Transition (GlobeNewswire)
Sep-11-23 08:00AM	Black Diamond Therapeutics Announces First Patients Dosed in Phase 1 Clinical Trial Expansion Cohorts Evaluating BDTX-1535 in Patients with Intrinsic Driver and Acquired Resistance EGFR Mutation Positive Non-Small Cell Lung Cancer (GlobeNewswire)
Sep-05-23 08:00AM	Black Diamond Therapeutics to Participate in Upcoming Investor Conferences (GlobeNewswire)
Aug-17-23 09:56AM	10 Healthcare Stocks with Insider Buying (Insider Monkey)
Aug-11-23 07:35AM	Black Diamond: Q2 Earnings Snapshot (Associated Press Finance)
07:30AM	Black Diamond Therapeutics Reports Second Quarter 2023 Financial Results and Provides Corporate Update (GlobeNewswire)
Jul-25-23 07:43AM	Is Black Diamond Therapeutics (NASDAQ:BDTX) In A Good Position To Invest In Growth? (Simply Wall St.)
Jul-16-23 10:05AM	TipRanks Perfect 10 List: These Monster Growth Stocks Could Reach New Highs (TipRanks)
Jun-29-23 08:57PM	Black Diamond Therapeutics Announces Pricing of Public Offering of Common Stock (GlobeNewswire) -12.22%
05:48PM	Why Shares of Black Diamond Therapeutics Skyrocketed This Week (Motley Fool)

Black Diamond Therapeutics, Inc. is a clinical-stage oncology company developing MasterKey therapies that target families of oncogenic mutations in patients with cancer. The company's MasterKey therapies are designed to address a broad spectrum of genetically defined tumors, overcome resistance, minimize wild-type-mediated toxicities, and be brain-penetrant to treat central nervous system diseases. It is currently focused on advancing a Phase 2 NSCLC trial of BDTX-1535, a brain-penetrant, fourth-generation epidermal growth factor receptor (EGFR) MasterKey inhibitor targeting EGFR-mutant NSCLC and glioblastoma. The company was founded by David M. Epstein and Elizabeth Buck in 2014 and is headquartered in Cambridge, MA.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
BIOTECH GROWTH N V	10% Owner	Mar 19 '25	Sale	2.07	5,784,292	11,997,749	2,733,547	Mar 20 09:01 PM

Open in Screener

CRSP

CRISPR Therapeutics AG

Feb 13 • 04:00PM ET

53.07

+4.14 8.46 %

Healthcare • Biotechnology • Switzerland • NASD

CRSP CRISPR Therapeutics AG daily Stock Chart

Peers: EDIT NTLA BEAM SGMO VRTX GILD BLUE ALLO CLLS ADPT

| Held by: ARKK ARKG IWM XBI VXF IWN IBB VTWO SCHA SCHM

Index	RUT	P/E	-	EPS (ttm)	-6.51	Insider Own	3.79%	Shs Outstand	95.89M	Perf Week	8.88%
Market Cap	5.09B	Forward P/E	-	EPS next Y	-3.77	Insider Trans	-6.05%	Shs Float	92.34M	Perf Month	-6.71%
Enterprise Value	3.32B	PEG	-	EPS next Q	-1.20	Inst Own	67.59%	Short Float	23.70%	Perf Quarter	1.69%
Income	-581.60M	P/S	1451.26	EPS this Y	25.98%	Inst Trans	1.99%	Short Ratio	11.58	Perf Half Y	-9.78%
Sales	3.51M	P/B	2.65	EPS next Y	21.18%	ROA	-25.81%	Short Interest	21.89M	Perf YTD	1.20%
Book/sh	20.04	P/C	2.57	EPS next 5Y	28.81%	ROE	-30.18%	52W High	78.48 -32.38%	Perf Year	22.03%
Cash/sh	20.66	P/FCF	-	EPS past 3/5Y	8.21% -4.10%	ROIC	-27.56%	52W Low	30.04 76.66%	Perf 3Y	3.03%
Dividend Est.	-	EV/EBITDA	-	Sales past 3/5Y	43.09% 37.31%	Gross Margin	-6534.67%	Volatility	5.53% 6.00%	Perf 5Y	-67.05%
Dividend TTM	-	EV/Sales	945.08	EPS Y/Y TTM	-49.45%	Oper. Margin	-16191.40%	ATR (14)	3.02	Perf 10Y	-
Dividend Ex-Date	-	Quick Ratio	13.32	Sales Y/Y TTM	-90.59%	Profit Margin	-16569.77%	RSI (14)	51.98	Recom	1.90
Dividend Gr. 3/5Y	- -	Current Ratio	13.32	EPS Q/Q	-214.02%	SMA20	2.05%	Beta	1.75	Target Price	81.17
Payout	-	Debt/Eq	0.11	Sales Q/Q	-97.58%	SMA50	-2.42%	Rel Volume	1.30	Prev Close	48.93
Employees	393	LT Debt/Eq	0.10	Earnings	Feb 12 AMC	SMA200	-1.52%	Avg Volume	1.89M	Price	53.07
IPO	Oct 19, 2016	Option/Short	Yes / Yes	EPS/Sales Surpr.	-17.81% -81.69%	Trades		Volume	2,463,922	Change	8.46%

Date	Action	Analyst	Rating Change	Price Target Change
Sep-18-25	Initiated	JP Morgan	Overweight	$70
Feb-14-25	Upgrade	Evercore ISI	In-line → Outperform	$60 → $99
Feb-12-25	Upgrade	TD Cowen	Sell → Hold	$35
Feb-03-25	Initiated	H.C. Wainwright	Buy	$65
Aug-06-24	Reiterated	Needham	Buy	$88 → $84
Aug-02-24	Initiated	Rodman & Renshaw	Buy	$90
Jun-28-24	Resumed	Guggenheim	Neutral
Feb-15-24	Initiated	Wolfe Research	Peer Perform
Dec-11-23	Downgrade	TD Cowen	Market Perform → Underperform	$30
Oct-17-23	Downgrade	Cantor Fitzgerald	Overweight → Neutral
Sep-27-23	Initiated	Mizuho	Buy	$82
Aug-17-23	Upgrade	Citigroup	Neutral → Buy
May-30-23	Initiated	William Blair	Outperform	$75
Apr-13-23	Initiated	Cantor Fitzgerald	Overweight	$72
Mar-21-23	Initiated	Bernstein	Mkt Perform	$44
Mar-17-23	Initiated	Bryan Garnier	Buy	$70
Mar-07-23	Initiated	Robert W. Baird	Neutral	$46
Oct-11-22	Initiated	Morgan Stanley	Underweight	$37
Aug-09-22	Downgrade	Barclays	Overweight → Equal Weight	$99 → $88
Jun-23-22	Downgrade	Evercore ISI	Outperform → In-line	$66 → $60

Show Previous Ratings

Today 09:06AM	Crispr Therapeutics price target raised to $74 from $62 at Evercore ISI (TipRanks)
09:05AM	Crispr Therapeutics price target raised to $82 from $80 at Needham (TipRanks)
Feb-13-26 01:45PM	CRISPR Therapeutics Spotlights Momentum For Lead Gene Therapy As Adoption Widens (Benzinga) +8.46%
11:53AM	VRTX's Q4 Earnings Miss Mark, Revenues Beat on Higher Product Sales (Zacks)
10:04AM	CRSP Posts Wider-Than-Expected Loss in Q4, Sales Miss Estimates (Zacks)
08:00AM	Loading…
08:00AM	Vertexs CRISPR therapy rebounds in latest earnings (BioPharma Dive)
Feb-12-26 06:00PM	CRISPR Therapeutics AG (CRSP) Reports Q4 Loss, Lags Revenue Estimates (Zacks)
04:30PM	CRISPR Therapeutics Provides Business Update and Reports Fourth Quarter and Full Year 2025 Financial Results (GlobeNewswire)
Feb-10-26 10:45AM	Vertex Gears Up to Report Q4 Earnings: Is a Beat in the Cards? (Zacks)
Feb-09-26 10:22AM	Zoetis Gears Up to Report Q4 Earnings: Here's What to Expect (Zacks)
Feb-06-26 09:00AM	CRISPR Therapeutics AG (CRSP) is Attracting Investor Attention: Here is What You Should Know (Zacks) +6.23%
Feb-05-26 07:28PM	Analyst Report: CRISPR Therapeutics AG (Morningstar Research) -8.55%
10:00AM	Vertex Pharmaceuticals (VRTX) Earnings Expected to Grow: What to Know Ahead of Next Week's Release (Zacks)
09:29AM	Neurocrine Biosciences to Report Q4 Earnings: What's in the Cards? (Zacks)
07:19AM	Citizens Maintains Outperform Rating On CRISPR Therapeutics (CRSP) Citing Undervalued Pipeline (Insider Monkey)
06:52PM	Loading…
Feb-04-26 06:52PM	Blue Bird Q1 Earnings Call Highlights (MarketBeat)
Feb-03-26 10:00AM	CRISPR Therapeutics AG (CRSP) Expected to Beat Earnings Estimates: Should You Buy? (Zacks)
08:30AM	CRSP to Report Q4 Earnings: Is a Beat in Store for the Stock? (Zacks)
Feb-02-26 05:50PM	CRISPR Therapeutics AG (CRSP) Surpasses Market Returns: Some Facts Worth Knowing (Zacks)
Jan-30-26 08:07AM	Cathie Wood Goes Bargain Hunting: 3 Stocks She Just Bought (Motley Fool) -6.35%
07:06AM	Cathie Wood Doubles Down on Joby Aviation After Stock Crashes 17% (GuruFocus.com)
Jan-29-26 12:48PM	Forget AI Stocks: This Biotech Could Cure What AI Can't Touch (Motley Fool)
07:18AM	BofA is Bullish on CRISPR Therapeutics AG (CRSP) (Insider Monkey)
Jan-27-26 04:33AM	Cathie Wood's Favorite Biotech Stock Is Under Pressure Amid Insider Sales And Slow Revenue Growth: Momentum Score Drops (Benzinga)
Jan-26-26 05:50PM	CRISPR Therapeutics AG (CRSP) Stock Sinks As Market Gains: Here's Why (Zacks)
09:00AM	CRISPR Therapeutics AG (CRSP) Is a Trending Stock: Facts to Know Before Betting on It (Zacks)
Jan-23-26 06:00PM	CRISPR Therapeutics AG (CRSP) Stock Declines While Market Improves: Some Information for Investors (Zacks) -8.70%
Jan-21-26 04:58PM	Cathie Wood Has 13 Big Ideas For 2026: Here's The Ark Invest List And Stocks To Watch (Benzinga) +11.11%
Jan-20-26 12:05AM	Cathie Wood's Ark Unleashes Cryptic ARKmoji Teasers To Showcase Its 'Big Ideas' For 2026: Can You Take A Guess At The Hidden Meaning? (Benzinga)
Jan-18-26 12:00PM	3 Seasonal Stocks to Buy Immediately (InvestorPlace)
05:50PM	Loading…
Jan-15-26 05:50PM	CRISPR Therapeutics AG (CRSP) Stock Declines While Market Improves: Some Information for Investors (Zacks)
Jan-13-26 09:00AM	Investors Heavily Search CRISPR Therapeutics AG (CRSP): Here is What You Need to Know (Zacks)
Jan-12-26 12:05PM	2 Biotech Stocks That Could Soar This Year (Motley Fool)
09:30AM	CRISPR Therapeutics (CRSP) Is Considered a Good Investment by Brokers: Is That True? (Zacks)
08:36AM	CRISPR Therapeutics Highlights Strategic Priorities and Anticipated 2026 Milestones (GlobeNewswire)
Jan-09-26 05:50PM	CRISPR Therapeutics AG (CRSP) Stock Slides as Market Rises: Facts to Know Before You Trade (Zacks)
Jan-06-26 07:06AM	Three Genomics Stocks Worth Tracking This Year (Zacks) +5.51%
Jan-05-26 06:00PM	CRISPR Therapeutics AG (CRSP) Laps the Stock Market: Here's Why (Zacks)
08:30AM	CRISPR Therapeutics to Present at the 44th Annual J.P. Morgan Healthcare Conference (GlobeNewswire)
Jan-02-26 01:29PM	Gene Therapy: 5 Biotech Stocks Chasing the $36B Prize (PR Newswire)
Dec-31-25 09:32AM	Can BEAM's Gene Editing Pipeline Create Long-Term Value Amid Rivalry? (Zacks)
Dec-30-25 11:49PM	Chardan Maintains A Buy Recommendation On CRISPR Therapeutics AG (CRSP) (Insider Monkey)
05:50PM	CRISPR Therapeutics AG (CRSP) Sees a More Significant Dip Than Broader Market: Some Facts to Know (Zacks)
09:00AM	Here is What to Know Beyond Why CRISPR Therapeutics AG (CRSP) is a Trending Stock (Zacks)
07:40AM	Contrarius Global Equity Fund's Thoughts on CRISPR Therapeutics' (CRSP) Gene Editing Therapy (Insider Monkey)
Dec-29-25 12:51PM	TSLA: Cathie Wood Dumps $30 Million Worth Tesla Stock (GuruFocus.com)
Dec-28-25 10:05AM	CRISPR Therapeutics Reports Strong 90% Response Rate and Lupus Remission in Landmark Zugo-Cel Update (Insider Monkey)
Dec-27-25 01:15PM	Cathie Wood drops $1.3 million on healthcare stock (TheStreet)
Dec-26-25 10:56AM	Cathie Wood Doubles Down on Self-Driving and Gene-Editing Stocks Ahead of 2026 (GuruFocus.com)
06:20AM	These 2 Healthcare Stocks Beat the Market in 2025. Should You Buy Them in 2026? (Motley Fool)
Dec-24-25 04:35AM	Is CRISPR Therapeutics Stock Yesterday's News? (Motley Fool)
Dec-23-25 05:50PM	CRISPR Therapeutics AG (CRSP) Stock Falls Amid Market Uptick: What Investors Need to Know (Zacks)
02:38PM	3 Brilliant Growth Stocks to Buy Now and Hold for the Long Term (Motley Fool)
10:35AM	CRSP Stock Rises on Encouraging Early Data From Zugo-Cel Studies (Zacks)
Dec-22-25 08:30AM	CRISPR Therapeutics Provides Broad Update on Zugocaptagene Geleucel (Zugo-cel; formerly CTX112) in Autoimmune Diseases and Hematologic Malignancies (GlobeNewswire)
Dec-19-25 09:00AM	Is Trending Stock CRISPR Therapeutics AG (CRSP) a Buy Now? (Zacks)
07:05AM	Is CRISPR Therapeutics a Buy, Sell, or Hold in 2026? (Motley Fool)
Dec-18-25 12:35PM	2 Growth Stocks to Invest $1,000 in Right Now (Motley Fool)
Dec-17-25 05:50PM	CRISPR Therapeutics AG (CRSP) Falls More Steeply Than Broader Market: What Investors Need to Know (Zacks)
Dec-16-25 10:50AM	2 Monster Stocks in the Making to Buy and Hold (Motley Fool)
Dec-15-25 11:30AM	12 Days of Investing: My Top 12 Stocks to Buy Before 2026 (Motley Fool)
Dec-12-25 01:05PM	2 Healthcare Stocks to Buy Ahead of the New Year (Motley Fool)
Dec-10-25 11:30AM	Why Is CRISPR Therapeutics (CRSP) Up 3.3% Since Last Earnings Report? (Zacks)
Dec-09-25 11:57AM	Beyond Traditional Drugs: Novel Platforms Targeting Hard-to-Treat Conditions (PR Newswire)
Dec-08-25 09:00AM	CRISPR Therapeutics AG (CRSP) is Attracting Investor Attention: Here is What You Should Know (Zacks)
Dec-07-25 09:45AM	2 Stocks That Could Soar by 52% and 282%, According to Wall Street (Motley Fool)
Dec-04-25 11:22PM	Analyst Report: CRISPR Therapeutics AG (Morningstar Research)
Dec-03-25 09:01AM	Vertex Up 9.2% in 3 Months: Should You Buy, Sell or Hold the Stock? (Zacks) +8.55%
Dec-01-25 05:28AM	What CRISPR Therapeutics' (CRSP) Latest Trial Results Mean for Investors (Insider Monkey)
Nov-30-25 04:10AM	Meet the Beaten-Down Biotech Stock Cathie Wood Loves That Wall Street Says May Soar 50% (Motley Fool)
Nov-29-25 01:23PM	The Best Stocks to Buy With $1,000 Right Now (Motley Fool)
01:08PM	Citizens Maintains Market Outperform on CRISPR Therapeutics (CRSP) Despite Casgevy Slowdown (Insider Monkey)
Nov-28-25 09:59AM	Can NTLA's In Vivo Pipeline Drive Long-Term Growth Amid Rivalry? (Zacks)
06:45AM	Cathie Wood Dumps Millions in Tesla -- Loads Up on Coinbase After Sharp Swings (GuruFocus.com)
Nov-25-25 09:00AM	CRISPR Therapeutics AG (CRSP) Is a Trending Stock: Facts to Know Before Betting on It (Zacks)
08:39AM	Oppenheimer Reaffirms Outlook on CRISPR Therapeutics (CRSP) After Encouraging Q3 Earnings Performance (Insider Monkey)
Nov-21-25 10:19AM	NTLA Declines 67% in a Month: Should You Buy, Sell or Hold the Stock? (Zacks)
04:31AM	3 Mid-Cap Growth Stocks That Have Mammoth Long-Term Potential (Motley Fool)
Nov-20-25 06:48PM	Analyst Report: CRISPR Therapeutics AG (Morningstar Research)
Nov-19-25 03:42PM	This Leading Gene-Editing Stock Could Be Going Private. Should You Buy Its Shares First? (Barchart) -5.12%
06:05AM	Missed Out on Eli Lilly? 2 Healthcare Stocks With Big Catalysts on the Horizon. (Motley Fool)
Nov-18-25 11:05AM	4 Struggling Stocks With "Harmless" Pullbacks (Schaeffer's Research)
08:48AM	Top 3 Genomics Stocks to Consider for Your Portfolio (Zacks)
04:45AM	RBC Capital Lifts CRISPR Therapeutics (CRSP) Target to $50, Keeps Sector Perform (Insider Monkey)
Nov-17-25 06:53AM	1 Underrated Stock That Could Soar by 58%, According to Wall Street (Motley Fool) +5.31%
Nov-14-25 09:00AM	CRISPR Therapeutics AG (CRSP) is Attracting Investor Attention: Here is What You Should Know (Zacks)
08:58AM	Can NTLA Stock Bounce Back in 2026 After Recent Pipeline Setbacks? (Zacks)
Nov-12-25 07:31AM	Cathie Wood Dumps $2.4 Million Worth Of Tesla Shares, Doubles Down On These AI Stocks (Benzinga) -5.47%
07:02AM	Cathie Wood doubles down on Alibaba: ARK Invest snaps up $25M in Chinese tech stocks (GuruFocus.com)
Nov-11-25 05:55PM	Analyst Report: CRISPR Therapeutics AG (Morningstar Research)
09:00AM	CRSP Posts Narrower-Than-Expected Loss in Q3, Sales Miss Estimates (Zacks)
Nov-10-25 04:58PM	Why Gene-Editing Giants Crispr Therapeutics And Intellia Therapeutics Diverged (Investor's Business Daily)
04:20PM	Merck's Heart Pill Slashes Cholesterol Levels in Test Patients (Barrons.com)
09:10AM	CRISPR Therapeutics AG (CRSP) Reports Q3 Loss, Lags Revenue Estimates (Zacks)
08:00AM	CRISPR Therapeutics Provides Business Update and Reports Third Quarter 2025 Financial Results (GlobeNewswire)
Nov-08-25 05:28PM	More Drugs to Fight High Cholesterol Are Emerging (The Wall Street Journal)
09:56AM	CRISPR Therapeutics Announces Positive Phase 1 Clinical Data for CTX310 Demonstrating Deep and Durable ANGPTL3 Editing, Triglyceride and Lipid Lowering (GlobeNewswire)
Nov-07-25 05:50PM	CRISPR Therapeutics AG (CRSP) Stock Drops Despite Market Gains: Important Facts to Note (Zacks)
Nov-05-25 11:35AM	VRTX's New Drugs Performance Mixed in Q3: Can Their Sales Improve? (Zacks)
Nov-04-25 04:13PM	Vertex Pharma's Mixed Quarter: How Legacy Products Drove Its Beat (Investor's Business Daily) -8.97%

CRISPR Therapeutics AG is a gene editing company, which engages in the development of transformative gene-based medicines for serious diseases using its proprietary CRISPR/Cas9 platform. Its CRISPR/Cas9 platform is a gene editing technology that allows for precise, directed changes to genomic DNA. The firm offers a portfolio of therapeutic programs across a broad range of disease areas including hemoglobinopathies, oncology, regenerative medicine, and rare diseases. The company was founded by Rodger Novak, Emmanuelle Charpentier, Shaun Patrick Foy, Matthew Porteus, Daniel Anderson, Chad Cowan, and Craig Mellow on October 31, 2013 and is headquartered in Zug, Switzerland.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Patel Naimish	Chief Medical Officer	Apr 03 '25	Buy	32.96	1,508	49,704	1,508	Jan 27 05:35 PM
Prasad Raju	Chief Financial Officer	Jan 22 '26	Option Exercise	45.15	34,972	1,578,986	41,739	Jan 26 05:35 PM
Prasad Raju	Chief Financial Officer	Jan 22 '26	Sale	60.19	34,972	2,104,965	6,767	Jan 26 05:35 PM
Kulkarni Samarth	Chief Executive Officer	Jan 22 '26	Sale	60.23	60,000	3,613,800	134,201	Jan 22 05:55 PM
Kulkarni Samarth	Chief Executive Officer	Jan 20 '26	Sale	51.75	30,000	1,552,498	194,201	Jan 22 05:55 PM
Samarth Kulkarni	Officer	Jan 22 '26	Proposed Sale	60.81	60,000	3,648,600		Jan 22 05:15 PM
RAJU PRASAD	Officer	Jan 22 '26	Proposed Sale	60.19	34,972	2,105,070		Jan 22 04:03 PM
Samarth Kulkarni	Officer	Jan 20 '26	Proposed Sale	52.61	30,000	1,578,300		Jan 20 05:11 PM
Prasad Raju	Chief Financial Officer	Jan 06 '26	Option Exercise	44.97	29,700	1,335,630	36,467	Jan 08 05:35 PM
Prasad Raju	Chief Financial Officer	Jan 06 '26	Sale	60.16	29,700	1,786,636	6,767	Jan 08 05:35 PM
RAJU PRASAD	Officer	Jan 06 '26	Proposed Sale	60.16	29,700	1,786,636		Jan 06 05:11 PM
Prasad Raju	Chief Financial Officer	Dec 22 '25	Sale	55.95	10,000	559,549	6,767	Dec 23 05:33 PM
RAJU PRASAD	Officer	Dec 22 '25	Proposed Sale	55.95	10,000	559,548		Dec 22 04:20 PM
Kulkarni Samarth	Chief Executive Officer	Oct 17 '25	Sale	67.91	50,895	3,456,279	254,201	Oct 20 05:35 PM
Kulkarni Samarth	Chief Executive Officer	Oct 14 '25	Sale	66.60	4,242	282,517	205,096	Oct 15 05:35 PM
KASINGER JAMES R.	General Counsel and Secretary	Oct 14 '25	Sale	66.60	1,076	71,662	83,402	Oct 15 05:35 PM
Kulkarni Samarth	Chief Executive Officer	Aug 18 '25	Sale	58.15	13,081	760,660	207,004	Aug 19 04:30 PM
Treco Douglas A	Director	Aug 06 '25	Buy	57.03	20,000	1,140,600	22,000	Aug 08 04:06 PM
George Simeon	Director	Jul 16 '25	Buy	52.03	989,812	51,499,918	1,730,179	Jul 17 05:19 PM
Patel Naimish	Chief Medical Officer	May 29 '25	Sale	35.94	3,932	141,316	6,068	May 30 05:00 PM
Kulkarni Samarth	Chief Executive Officer	Mar 21 '25	Sale	41.23	10,031	413,578	195,085	Mar 24 05:35 PM
Bruno Julianne	Chief Operating Officer	Mar 21 '25	Sale	41.23	1,714	70,668	10,544	Mar 24 05:35 PM
Prasad Raju	Chief Financial Officer	Mar 21 '25	Sale	41.23	2,197	90,582	16,767	Mar 24 05:35 PM
KASINGER JAMES R.	General Counsel and Secretary	Mar 21 '25	Sale	41.23	3,185	131,318	81,729	Mar 24 05:35 PM
Prasad Raju	Chief Financial Officer	Mar 17 '25	Sale	41.80	3,762	157,252	12,714	Mar 18 05:35 PM
Kulkarni Samarth	Chief Executive Officer	Mar 11 '25	Sale	42.42	9,973	423,055	180,890	Mar 12 07:05 PM
Kulkarni Samarth	Chief Executive Officer	Mar 12 '25	Sale	43.32	4,462	193,294	185,428	Mar 12 07:05 PM
KASINGER JAMES R.	General Counsel and Secretary	Mar 11 '25	Sale	42.42	2,850	120,897	77,530	Mar 12 07:05 PM
KASINGER JAMES R.	General Counsel and Secretary	Mar 12 '25	Sale	43.32	1,116	48,345	78,664	Mar 12 07:05 PM
Bruno Julianne	Chief Operating Officer	Mar 11 '25	Sale	42.42	1,198	50,819	8,263	Mar 12 07:05 PM
Bruno Julianne	Chief Operating Officer	Mar 12 '25	Sale	43.32	190	8,231	8,508	Mar 12 07:05 PM
Greene John	Director	Feb 26 '25	Buy	44.85	7,000	313,948	7,000	Feb 28 05:35 PM
Kulkarni Samarth	Chief Executive Officer	Feb 19 '25	Sale	55.20	18,360	1,013,564	171,613	Feb 21 05:35 PM
Kulkarni Samarth	Chief Executive Officer	Feb 18 '25	Sale	55.05	11,640	640,782	196,901	Feb 19 05:35 PM
Kulkarni Samarth	Chief Executive Officer	Feb 19 '25	Sale	52.80	6,928	365,798	189,973	Feb 19 05:35 PM
Bruno Julianne	Chief Operating Officer	Feb 19 '25	Sale	52.80	333	17,582	7,062	Feb 19 05:35 PM
KASINGER JAMES R.	General Counsel and Secretary	Feb 18 '25	Sale	53.85	9,595	516,691	73,002	Feb 19 05:35 PM
KASINGER JAMES R.	General Counsel and Secretary	Feb 19 '25	Sale	52.80	1,947	102,802	74,880	Feb 19 05:35 PM
Samarth Kulkarni	Officer	Feb 18 '25	Proposed Sale	52.22	45,000	2,349,900		Feb 18 05:35 PM

BDTX

Black Diamond Therapeutics Inc

CRSP

CRISPR Therapeutics AG

Upgrade your FINVIZ experience